Custom mRNA Vaccine Cuts Melanoma Recurrence Risk in Trial
A Merck-Moderna mRNA vaccine combined with Keytruda lowered melanoma recurrence or death by 42% in a pivotal study, prompting discussion of broader cancer-vaccine applications.
A pivotal trial presented at the European Society for Medical Oncology meeting in Madrid showed that a personalized mRNA vaccine, intismeran, reduced the risk of melanoma recurrence or death by 42% when used together with Merck's checkpoint inhibitor Keytruda, compared with Keytruda alone. The study, conducted by Merck and Moderna, marks a significant milestone for cancer-vaccine research.
"In principle, this type of approach may be applicable to other types of tumors," said James Larkin of the Royal Marsden Hospital, who co-chaired the meeting's scientific program.
The results have sparked conversation among melanoma specialists about how to integrate the therapy into clinical practice and whether similar vaccine strategies could be extended to other cancers.
Vinod Balachandran of Memorial Sloan Kettering Cancer Center described the field's prior attempts as a "long and sordid" history of efforts that had not yielded effective vaccines.
Researchers emphasized that the trial's outcome provides a new direction for developing tailored cancer immunotherapies, though further studies will be needed to assess safety, scalability and effectiveness across different tumor types.